neurometrix_rgb.jpg
NeuroMetrix Reports Q1 2022 Financial Results
April 26, 2022 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to...
neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call
April 19, 2022 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on...
neurometrix_rgb.jpg
NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome
February 24, 2022 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell wearable neuromodulation technology will be evaluated for treatment of a...
neurometrix_rgb.jpg
NeuroMetrix Reports Q4 and Full Year 2021 Financial Results
January 27, 2022 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2021. The...
neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call
January 20, 2022 12:10 ET | NeuroMetrix, Inc.
WOBURN, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 fourth quarter and full year financial results before the opening of...
neurometrix_rgb.jpg
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology
January 18, 2022 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that its Quell® technology has received Breakthrough Designation from the U.S. Food and Drug...
neurometrix_rgb.jpg
NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022
January 05, 2022 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, will be presenting at the...
neurometrix_rgb.jpg
NeuroMetrix Reports Q3 2021 Financial Results
October 21, 2021 07:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended September 30, 2021. The Company is a leader...
neurometrix_rgb.jpg
NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care
October 20, 2021 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Susan M. Bell as Senior Vice President, Population Health & Value Based...
neurometrix_rgb.jpg
NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Call
October 14, 2021 09:00 ET | NeuroMetrix, Inc.
WOBURN, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 third quarter financial results before the opening of the market on...